Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Feb 12, 2009

Premium

Title: RNAi-Related Inhibition of TNFa Signaling Pathway for Treatment of Glaucoma

Number: 20090035225

Filed: Aug. 1, 2008

Lead Inventor: Jon Chatterton, Alcon

The patent application, its abstract states, claims RNA interference for the “inhibition of tumor necrosis factor-alpha by silencing [the] TNF-alpha cell-surface receptor TNF receptor-1 mRNA expression, or by silencing TNF-alpha-converting enzyme mRNA expression. Silencing such TNF-alpha targets … is useful for treating patients having a TNF-alpha-related condition or at risk of developing a TNF-alpha-related condition such as the ocular conditions associated with elevated intraocular pressure, including glaucoma and ocular hypertension.”


Title: Methods and Compositions for the Specific Inhibition of Gene Expression by Double-Stranded RNA

Number: 20090035854, 20090036661

Filed: June 20, 2008

Lead Inventor: John Rossi, City of Hope (Integrated DNA Technologies)

“The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene,” the patent application’s abstract states. “More particularly, the invention is directed to compositions that contain double-stranded RNA, and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions,” the abstract notes. “In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.”


Title: RNAi Medicine Having No Adverse Effects

Number: 20090035861

Filed: Jan. 27, 2006 PCT Filed: Jan. 27, 2006

Lead Inventor:
Hiroshi Takaku, Niigata University of Pharmacy and Applied Life Sciences

The invention, the patent application’s abstract states, comprises “an RNAi reagent and a medicine that have no adverse effects such as interferon and/or cytotoxicity induction.” Specifically, the application claims “an shRNA used for sequence-specific RNA interference without interferon and/or cytotoxicity induction and a medicine and a reagent containing the shRNA,” according to the abstract. The shRNA comprises “a sense strand [with] a sequence homologous to a target sequence of the target mRNA and an antisense strand [with] a sequence complementary to the sequence of the sense strand, [as well as] an overhang comprising one or a plurality of Gs at the 5’ end of the sense strand.”


Title: RNA Interference Supression of Neurodegenerative Diseases and Methods of Use Thereof

Number: 20090036395

Filed: April 28, 2008

Lead Inventor:
Beverly Davidson, University of Iowa

The invention, the patent application’s abstract states, “is directed to RNA interference molecules targeted against a nucleic acid sequence that encodes poly-glutamine repeat diseases, and methods of using these RNAi molecules.”


Title: RNAi-Related Inhibition of TNF-Alpha Signaling Pathway for Treatment of Ocular Angiogenesis

Number: 20090036396

Filed: Aug. 1, 2008

Lead Inventor:
Jon Chatterton, Alcon

The invention, the patent application’s abstract states, claims “RNA interference … for inhibition of tumor necrosis factor-alpha by silencing TNF-alpha cell-surface receptor TNF receptor-1 mRNA expression, or by silencing TNF-alpha-converting enzyme mRNA expression. Silencing such TNF-alpha targets … is useful for treating patients having a TNF-alpha-related condition or at risk of developing a TNF-alpha-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.”


Title: RNAi-Related Inhibition of TNFa Signaling Pathway for Treatment of Macular Edema

Number:
20090036397

Filed:
Aug. 4, 2008

Lead Inventor:
Jon Chatterton, Alcon

The invention, the patent application’s abstract states, claims “RNA interference … for inhibition of tumor necrosis factor-alpha by silencing TNF-alpha cell-surface receptor TNF receptor-1 mRNA expression, or by silencing TNF-alpha-converting enzyme mRNA expression. Silencing such TNF-alpha targets … is useful for treating patients having or at risk of developing macular edema.”

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.